Corporate Presentation AUGUST 2022 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward looking statements by t ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Eben Tessari - Chief Operating Officer Mark Ragosa - Chief Financial Officer Ross Moat - Chief Commercial Officer Conference Call Participants Jason Zemansky - Bank of America Anupam Rama - JPMorgan Operator Good morning and welcome to the Kiniksa Pharmaceuticals Second Quarter 2022 Financial Earnings Confer ...

| --- | --- | --- | --- | |-----------------------|-------|-------|-------| | | | | | | Second Quarter 2022 | | | | | | | | | | Financial Results and | | | | AUG UST 3, 2022 Agenda | --- | --- | |---------------------------------------------------------------------------------------|-------| | Introduction \| Sanj K. Patel, Chief Executive Officer | | | Review of License Agreement for Vixarelimab \| Eben Tessari, Chief Operating Officer | | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Incorporation or Organization) Identification No.) Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Rachel Frank - Head of IR Sanj Patel - CEO and Chairman Ross Moat - Chief Commercial officer Mark Ragosa - CFO John Paolini - Chief Medical Officer Eben Tessari - COO Conference Call Participants Anupam Rama - JPMorgan. Paul Choi - Goldman Sachs David Nierengarten - Wedbush Securities Alexandria Hammond - Geoff Meacham Liisa Bayko - Evercore ISI Operator Good day, and thank you for standing by ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Other Ju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Q4 2021 Results Earnings Conference Call February 22, 2022 8:30 AM ET Company Participants Rachel Frank - Associate Director, Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Senior Vice President and Chief Commercial Officer Eben Tessari - Chief Operating Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Anupam Rama - J.P. Morgan Paul Choi - Goldman Sachs David Nierengarten - ...

| --- | --- | --- | --- | --- | |------------------|-------|-------|----------------------------|------------------------------| | | | | | | | | | | | Fourth Quarter and Full-Year | | | | | 2021 Financial Results and | | | | | | | | | Corporate Update | | | | | FEBRUARY 22, 2022 Agenda | --- | --- | |---------------------------------------------------------------------------|--------------------------------------| | Introduction \| Sanj K. Patel, Chief Executive Officer | | | ARCALYST® Commercial Execution ...

JP Morgan Conference Presentation JANUARY 2022 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward looking sta ...